141 related articles for article (PubMed ID: 16801454)
1. Separation of binding affinity and intrinsic activity of the potent mu-opioid 14-methoxymetopon.
Mahurter L; Garceau C; Marino J; Schmidhammer H; Tóth G; Pasternak GW
J Pharmacol Exp Ther; 2006 Oct; 319(1):247-53. PubMed ID: 16801454
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
[TBL] [Abstract][Full Text] [Related]
3. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.
Selley DE; Liu Q; Childers SR
J Pharmacol Exp Ther; 1998 May; 285(2):496-505. PubMed ID: 9580589
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
6. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
[TBL] [Abstract][Full Text] [Related]
7. Mu opioid receptor coupling to Gi/o proteins increases during postnatal development in rat brain.
Talbot JN; Happe HK; Murrin LC
J Pharmacol Exp Ther; 2005 Aug; 314(2):596-602. PubMed ID: 15860573
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor.
Alt A; Mansour A; Akil H; Medzihradsky F; Traynor JR; Woods JH
J Pharmacol Exp Ther; 1998 Jul; 286(1):282-8. PubMed ID: 9655870
[TBL] [Abstract][Full Text] [Related]
9. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S
Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
[TBL] [Abstract][Full Text] [Related]
11. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
Chen F; Lawrence AJ
J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
[TBL] [Abstract][Full Text] [Related]
12. Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist.
Spetea M; Tóth F; Schütz J; Otvös F; Tóth G; Benyhe S; Borsodi A; Schmidhammer H
Eur J Neurosci; 2003 Jul; 18(2):290-5. PubMed ID: 12887410
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration.
Maher CE; Martin TJ; Childers SR
Life Sci; 2005 Jul; 77(10):1140-54. PubMed ID: 15890372
[TBL] [Abstract][Full Text] [Related]
14. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
15. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
16. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
Vogt LJ; Sim-Selley LJ; Childers SR; Wiley RG; Vogt BA
J Pharmacol Exp Ther; 2001 Dec; 299(3):840-8. PubMed ID: 11714867
[TBL] [Abstract][Full Text] [Related]
17. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
Xu H; Lu YF; Rothman RB
Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
[TBL] [Abstract][Full Text] [Related]
18. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons.
Zollner C; Shaqura MA; Bopaiah CP; Mousa S; Stein C; Schafer M
Mol Pharmacol; 2003 Aug; 64(2):202-10. PubMed ID: 12869624
[TBL] [Abstract][Full Text] [Related]
19. Delta and mu opioid receptors from the brain of a urodele amphibian, the rough-skinned newt Taricha granulosa: cloning, heterologous expression, and pharmacological characterization.
Bradford CS; Walthers EA; Stanley DJ; Baugh MM; Moore FL
Gen Comp Endocrinol; 2006 May; 146(3):275-90. PubMed ID: 16375901
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone-induced upregulation of mu opioid receptors on 7315c cell and brain membranes: enhancement of opioid efficacy in inhibiting adenylyl cyclase.
Côté TE; Izenwasser S; Weems HB
J Pharmacol Exp Ther; 1993 Oct; 267(1):238-44. PubMed ID: 8229750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]